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ABSTRACT The HLA-D locus in the major histocompatibility
complex controls the expression of the genetically polymorphic
HLA-DR antigens. mRNA coding for the A chains of these anti-
gens was partially purified from the human lymphoblastoid cell
line Raji. The mRNA was copied into double-stranded cDNA and
cloned in Escherichia coli. One clone, pDR-(3-1, obtained by hy-
brid selection, carries a 1070-base-pair insert comprising all of the
coding region except the signal sequence and a substantial portion
of the untranslated region. To identify pDR-.3-1, highly purified
HLA-DR antigen (3 chains derived from Raji cells were subjected
to NH2-terminal amino acid sequence determination. This se-
quence displayed extensive homology with that deduced from the
nucleotide sequence at the 5' end of the pDR-P-I coding region.
Taken together, the amino acid and nucleotide sequences strongly
argue in favor of Raji cells containing at least two (-chain loci.
HLA-DR histocompatibility antigens are cell surface proteins
present on different subclasses of lymphocytes and macro-
phages (1). However, recently it was demonstrated that expres-
sion of these antigens is not strictly limited to cells of the im-
mune system: they also occur on other types of cells such as
epithelial cells in various organs (2). The molecular functions
of the HLA-DR antigens, and of their murine counterparts the
Ia antigens, are largely unknown. However, their role in several
immunobiological phenomena is well documented. Expression
of Ia antigens on the antigen-presenting cell seems to be a pre-
requisite for the proper activation of T-helper cells (3). Like-
wise, the cooperation between T-helper cells and B lympho-
cytes is controlled by the HLA-DR (Ia) antigens (4).
HLA-DR antigens are composed of two noncovalently
linked, glycosylated, polypeptide chains with apparent molec-
ular weights of35,000 and 29,000, respectively (5). The smaller
one, the 13 chain, displays most of the extensive genetic poly-
morphism (6, 7). Such polymorphism is a puzzling, common
feature of molecules controlled by the major histocompatibility
complex. The other chain, the a chain, is much less poly-
morphic than the 1 chain (6, 7).
The murine Ia antigens are controlled by two distinct subloci
called I-A and I-E/C (8). Limited NH2-terminal amino acid se-
quence analyses have revealed that I-Aa,, I-A., I-E/C,,, and I-
E/Cp chains display unique primary structures (8, 9). Corre-
sponding structural analyses of highly purified HLA-DR anti-
gens have revealed only the existence of E/C-like sequences
(10). However, recent data based on serological tests and two-
dimensional electrophoretic analyses suggest that HLA-DR an-
tigens may be controlled from more than one locus (11, 12).
Structural analyses of HLA-DR antigens lag behind those of
HLA-A, -B, and -C antigens (13). In this communication we
describe the isolation and partial characterization of an HLA-
DR antigen 1-chain cDNA clone. The insert in the clone cor-
responds to most if not all of the translated portion of a 1 chain.
MATERIALS AND METHODS
Materials. S1 nuclease and terminal deoxynucleotidyl trans-
ferase were obtained from Bethesda Research Laboratories;
DNA polymerase I was from Boehringer Mannheim. Polynu-
cleotide kinase and restriction enzymes were purchased from
New England BioLabs. (dT)1218 and oligo (dT)-cellulose were
from Collaborative Research (Waltham, MA). Rabbit reticulo-
cyte lysate, [3S]methionine, and EN3HANCE were the prod-
ucts ofNew England Nuclear. [a-32P]Deoxynucleotides (>400
Ci/mmol; 1 Ci = 3.7 x 101° becquerels) and adenosine
[y-32P]triphosphate (>2000 Ci/mmol) were obtained from the
Radiochemical Centre (Amersham, England). Nitrocellulose
filters (BA 85) were purchased from Schleicher & Schuell.
Antiserum. An antiserum against HLA-DR antigen 13 chains
was raised in a rabbit by immunization with highly purified P
chains. HLA-DR antigens were purified to homogeneity and
a and (3 chains were separated from each other by preparative
NaDodSOJpolyacrylamide gel electrophoresis. The antiserum
obtained did not crossreact with HLA-DR antigen a chains.
Cultivation ofRaji Cells. The human lymphoblastoid cell line
Raji (HLA-Dw 3 and 6) was maintained in roller-flask cultures
containing RPMI-1640 medium (GIBCO) and 10% neonatal calf
serum. RNA was isolated from cells in logarithmic growth
phase.
Isolation of mRNA. Microsomal mRNA was isolated from
Raji cells according to a protocol described elsewhere (14). En-
richment of mRNA coding for HLA-DR antigen subunits was
accomplished by centrifugation of the mRNA in a 10-30%
aqueous sucrose gradient for 11 hr at 39,000 rpm in a Beckman
SW 40 rotor at 15'C. Distribution of HLA-DR antigen mRNA
in the gradient was determined by cell-free translation (15).
Preparation ofcDNA Clones. Sucrose density gradient frac-
tions enriched for HLA-DR antigen mRNA were transcribed
into cDNA with use of avian myeloblastosis virus reverse tran-
scriptase (a generous gift of J. W. Beard, National Institutes of
Health). The second strand was synthesized with DNA poly-
merase I. The conditions for first- and second-strand synthesis
described by Wickens et al. were used (16). After treatment of
the cDNA with S1 nuclease as outlined by Hoeijmakers et al.
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(17), the material was size fractionated~on a 5-23% sucrose gra-
dient (17). Molecules longer than 600 base pairs were tailed with
deoxycytidine (18), and'the tailed cDNA was hybridized to Pst
I-digested pBR322 (19) elongated with deoxyguanosine (18).
The resulting hybrid molecules were used to transform Esch-
erichia coli strain 294 (20, 21).- Preparation of competent cells
was performed according to Dagert and Erlich (22).
Purification ofPlasmid DNA. Tetracycline-resistant colonies
were grown in L broth and amplified by the addition of chlor-
amphenicol (200 Ag/ml) at an optical density of 0.6 at 600 nm.
Cleared lysates were prepared as described (23). Plasmids were
purified by centrifugation in a CsCVethidium bromide density
gradient. For restriction mapping and sequence determination,
plasmid DNA was further purified by centrifugation in a 5-40%
sucrose gradient (24) or by chromatography on a column of
Sepharose 4B.
mRNA Selection by Hybridization on Nitrocellulose Filters.
Plasmid DNA was sonicated into pieces ranging from 0.3 to 1
kilobase. The DNA was denatured in 0.1 M NaOH for 10 min
on ice. After neutralization with NaH2PO4, the DNA (60 ttg)
was immobilized onto 25-mm-diameter nitrocellulose filters.
Four micrograms of mRNA was hybridized to each filter. The
conditions for the hybridization have been described (25). For
rapid screening; plasmid DNA from eight different recombi-
nant clones was immobilized on the same filter. When a positive
signal was obtained, the clones were rescreened individually.
Cell-Free Translation. The eluted mRNA was translated' in
a rabbit reticulocyte lysate system in the presence of dog pan-
creas microsomes (15). An aliquot (2 Al) of the translated prod-
ucts was characterized directly by NaDodSOjpolyacrylamide
gel electrophoresis (15). The remainder (23 Al) was subjected
to immunoprecipitation using an antiserum specific for HLA-
DR antigen A chains. In some cases, proteins translated in the
presence of microsomes were subjected to proteinase K treat-
ment to digest the cytoplasm tail of membrane-integrated pro-
teins (15). Precipitated proteins were analyzed by NaDodSOg
polyacrylamide gel electrophoresis and fluorography. The de-
tailed procedures are described in ref. 15.
Restriction Mapping and DNA Sequence Analysis. The re-
striction map was constructed as described (26). For DNA se-
quence determination, the DNA was cleaved with a suitable
restriction endonuclease and labeled with [y-32P]ATP at the 5'
ends (27). DNA fragments were then cleaved a second time to
produce fragments with only one labeled end. Purification of
DNA fragments for sequence determination was accomplished
by polyacrylamide gel electrophoresis and electroelution into
dialysis bags. Sequence determination was performed accord-
ing to Maxam and Gilbert (27) and Maat and Smith (28).
Amino Acid Sequence Determinations of HLA-DR Antigen
.8 Chains. Raji cells were separately labeled with [3H]leucine,[3H]phenylalanine, [3H]tyrosine, and [3S]methionine (Radi-
ochemical Centre, Amersham, England) according to a pub-
lished protocol (29). Radiolabeled HLA-DR antigen 8 chains
were isolated and subjected to amino acid sequence determi-
nations. In each case the ( chains contained only a single type
of radioactive amino acid. The details of the methods are out-
lined elsewhere (29).
Milligram amounts ofhighly purified'HLA-DR antigens from
Raji cells (5) were subjected to preparative NaDodSOJpoly-
acrylamide gel electrophoresis to separate a and (3 chains. The
HLA-DR antigen subunits were extracted from the gel, di-
alyzed against distilled water, and lyophilized. The (-chain frac-
tion was subjected to automatic amino acid sequence deter-
mination in a Beckman 890 C sequencer (30). Phenylthiohydan-
toin derivatives of the amino acids were identified by high-
pressure liquid chromatography (31).
Biosafety. All work involving recombinant plasmids was done
under conditions conforming to the standards outlined in the
National Institutes of Health guidelines for recombinant DNA
research.
RESULTS
Construction ofPlasmidpDR-l.&3 RNA coding for HLA-DR
antigen chains was isolated from a crude microsome fraction of
Raji cells. After selection for poly(A)-containing mRNA, an ali-
quot was subjected to cell-free translation. Approximately
0.01% of the [3S]methionine-labeled product was precipitated
by the antiserum against HLA-DR antigen (3 chains. After size
separation ofthe mRNA by sucrose gradient centrifugation, the
purity of the (3chain mRNA increased 10-fold as evidenced by
cell-free translation, immunoprecipitation, and NaDodSOJ
polyacrylamide gel electrophoresis. Fractions containing (3-
chain mRNA were combined and concentrated.
From the fractions containing HLA-DR antigen (3-chain
mRNA, 10 gg was copied into double-stranded cDNA and
cloned into Escherichia coli. Double-strandedcDNA molecules
recombined with Pst I-digested pBR322 yielded 1500 tetracy-
cline-resistant, ampicillin-sensitive colonies after transforma-
tion. Plasmid DNA that was purified from individual colonies
and combined into groups of eight was immobilized onto nitro-
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FIG. 1. Identification of pDR-3-1 by hybridization-selection and
cell-free translation. Plasmid DNAs were immobilized onto nitrocel-
lulose filters and hybridized with. Raji mRNA. After elution, the
mRNA was translated in a cell-free system. Translation products were
characterized by NaDodSO/polyacrylamide gel electrophoresis and
autoradiography. Lanes: 1, total translation products, in the absence
of microsomes, of Raji mRNA used for hybridization to pDR-,-1 DNA;
2, as lane 1 but in the presence of microsomes; 3, total translation prod-
ucts in the presence of microsomes of Raji mRNA hybridized to pDR-
,-1 DNA; 4, as lane 3 but after precipitation with an anti-HLA-DR
antigen 3-chain antiserum; 5, after translation of Raji mRNA hybrid-
ized to pDR-(-1, the microsomes were treatedwith proteinase K (15)
prior to immunoprecipitation of the (3-chain; 6, 7, and 8, translation
products of Raji mRNA hybridized to two separate recombinant plas-
mids containing unidentified inserts and to pBR322, respectively. All
translations were carried out in the presence of microsomes except in
lane 1. Translation products were precipitated with an HLA-DR an-
tigen (-chain antiserum except in lanes 1-3. Arrows, positions of
markers (kilodaltons).
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FIG. 2. Restriction map of the pDR-3-1 cDNA insert. The 1070-base-pair insert is drawn as a straight line with flanking pBR322 sequences,
as it is oriented in the plasmid (with the EcoRI site close to the right-hand side of the insert). The 5' end of the coding strand is to the left. The part
of the insert whose sequence was determined is shown as a box, and the strategy is indicated by the arrows. The bold arrow indicates sequence
obtained by the method of Maat and Smith (28). Thin arrows indicate sequence obtained by the Maxam and Gilbert method (27). Fragments were
isolated from pDR-,3-1 as follows: (i) cut with Pst I, labeled, recut with EcoRI, 790-base-pair fragment isolated; (ii) cut with Ava I, labeled, recut
with Sac I, 250-base-pair fragment isolated; (iii) cut withAva II, labeled, recutwithAva I, 140-base-pair fragment isolated. Fragment i was analyzed
by both methods.
cellulose filters for the selection by hybridization ofmRNA cod-
ing for HLA-DR. antigen chains. The hybridized mRNA was
eluted and then translated in a cell-free system containing dog
pancreas microsomes. After translation, the microsomes were
isolated and analyzed for content ofnewly synthesized HLA-DR
antigen chains by immunoprecipitation and NaDodSOJ
polyacrylamide gel electrophoresis.
By using this selection method, 1 of40 filters tested was pos-
itive (i.e., hybridized to (-chain mRNA). Plasmid DNA from
each one of the eight bacterial colonies comprising the mixture
present on the positive filter was immobilized separately onto
nitrocellulose filters. The selection procedure was subsequently
repeated and one positive clone was obtained. The mRNA
eluted from this plasmid DNA directed the synthesis of a major
polypeptide chain with an apparent molecular weight of about
28,000 (Fig. 1, lane 3). This polypeptide was precipitated by the
antiserum against HLA-DR antigen chains (lane 4) and co-
migrated with core-glycosylated P chains of Raji cells (not
shown). Moreover, proteinase K digestion of the microsomes
after the translation removed approximately 1000 daltons from
the putative chain (lane 5).
This result is in agreement with the observation that the (3
chain is a transmembrane protein. Other plasmids and the vec-
tor (Fig. 1, lanes 6-8) did not give rise to any immunoprecip-
itable polypeptide chain. The identified plasmid, named pDR-
,B31, was used to generate restriction enzyme fragments of the
insert. Colony hybridization was carried out with such labeled
fragments (32). From the original 1500 clones, 2 more were
identified as positive by this procedure. Detailed analyses of
these clones will be reported elsewhere.
Partial Characterization of the pDR-,-1 Insert. A restric-
tion map of the pDR-(3-1 cDNA insert is shown in Fig. 2. The
insert contains 1070 base pairs.- Only the left Pst I site was re-
constituted. Three cleavage sites for Pvu II, two for Ava I, and
one for Sac I, Taq I, Ava II, and EcoRI were found in the insert.
Nucleotide sequence determinations were carried out from
both ends of the insert. No stretch of poly(A) residues was ob-
served. However, stop codons were found in all reading frames
in the sequence close to the right-hand side of the insert. This
is a strong indication that this portion ofthe cDNA corresponds
to the noncoding region of the mRNA. Consequently, the left-
hand side of the insert corresponds to the coding portion. The
sequence of 150 nucleotides at the left-hand side of the insert
is depicted in Fig. 3. Following 21 or 22 guanosines belonging
to the poly(G)tail, the sequence ofthe insert most likely begins.
Only one open reading frame exists. That reading frame pro-
vides unambiguous information for the amino acid sequence
shown in the figure apart from the NH2-terminal glycine (see
below).
NH2-Terminal Amino Acid Sequence Determination of Raji
HLA-DR Antigen f3 Chains. Detergent-solubilized HLA-DR
antigens were isolated from Raji cells. During the isolation pro-
cedure, which involved several fractionation steps (5), the oc-
currence of HLA-DR antigens was monitored both by a ra-
dioimmunoassay method and by NaDodSOjpolyacrylamide
gel electrophoresis. When no contaminating proteins could be
detected in the HLA-DR antigen preparation, a and P chains
were separated by preparative NaDodSOjpolyacrylamide gel
electrophoresis. The (3-chain fraction was subjected to auto-
matic NH2-terminal amino acid sequence analysis. In 33 of the
35 degradation cycles performed, phenylthiohydantoin amino
acid derivatives could be detected (Fig. 4). For seven positions,
more than a single amino acid residue was found, supporting
the fact that Raji cells are heterozygous at the HLA-D locus.
Because ofthe known genetic polymorphism ofthe HLA-DR
antigen chains (6, 7) we wished to confirm that the protein
sequence was representative for the Raji cells. Accordingly,
HLA-DR antigen (3 chains derived from Raji cells separately
25 50 75
pDR- B- 1 (G) 22AG GGC AGA GAC TCT CCC GAG GAT TTC GTG TAC CAG TTT AAG GGC ATG TGC TAC TTC ACC AAC GGG
Ge q-Arg-Asp-Ser-Pro-Glu-Asp-Phe-Val-Tyr-Gln-Phe-Lys-Gly-Met-Cys-Tyr-Phe-Thr-Asn-Gly-
100 125 0SO
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Thr-Glu-Arg-Val-Arg-Leu-Val-Ser-Arg-Ser-Ile-Tyr-Asn-Arg-Glu-Glu-Val-Val-Arg-Phe-Asp
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FIG. 4. Yields of phenylthiohydantoin derivatives in the amino
acid sequence determination on 14 nmol of HLA-DR antigen ,3 chain.
The one-letter amino acid code is used. X, unidentified residue.
labeled withtUnS]methionine, [3H]phenylalanine, [3H]tyrosine,
and [3H]leucine were subjected to automatic amino acid se-
quence analyses. By this procedure, 11 of 30 positions in the
NH2-terminal portion of the Raji (3 chains were assigned one
or more amino acid residues (Fig. 5). Seven of the 11 positions
displayed the same residues as those obtained by analyzing the
unlabeled chains.
The varying yields of the radioactive phenylthiohydantoin
derivatives clearly demonstrated that the Raji chains were
heterogeneous in amino acid sequence. For instance, the ty-
rosine in position 7 gave a lower yield than that in position 10.
Likewise, the phenylalanine in position 11 was recovered in
smaller amounts than that in position 13. These data together
with the fact that 4 of the 11 positions analyzed by the radi-
ochemical method displayed amino acid residues not found in
pDR-(3-1
the sequence of the unlabeled 3 chains strongly indicate that
the (3chain family of Raji cells is greater than revealed by the
sequence analysis of the unlabeled material.
Identification ofpDR-fi-1 As an HLA-DR Antigen 3-Chain-
Like Clone. Fig. 5 shows the NH2-terminal amino acid se-
quences of HLA-DR antigen (3 chains as determined on the
unlabeled (middle row) and on the biosynthetically labeled sub-
unit (bottom row). The amino acid sequence deduced from the
nucleotide sequence of the pDR-f3-1 insert is also shown (top
row). In the region available for comparison (i.e., 33 positions),
pDR--3-1 displays an overall homology to the combined protein
sequences of64%. To maximize the homology, the penultimate
arginine of pDR-/3-1 has to be aligned with the NH2 terminus
of the protein sequences. This. suggests that the NH2-terminal
glycine of pDR-f3-1 represents the last residue of the signal se-
quence. However, the glycine residue should be regarded as
tentative because a single adenosine separates the poly(G)tail
from three additional guanosines, two of which are part of the
glycine codon. Thus, the adenosine may be an artifact which
arose during the tailing reaction.
The homology between the protein sequence of the unla-
beled material and pDR-,8-1 is 48% whereas the homology be-
tween the radiochemical sequence and pDR-(3-1 is 64%. Those
positions in the unlabeled (-chain sequence corresponding to
the known ones in the radiochemical sequence show only 18%
homology with pDR-,(31.
DISCUSSION
To clone HLA-DR antigen 3-chain cDNA, we used methods
that proved successful in cloning H-2 antigen cDNA (14). There
seems to be three key features related to using this protocol.
First, the mRNA has to be enriched because Raji cells contain
relatively small amounts of P-chain mRNA. Although size sep-
aration by sucrose gradient centrifugation is an efficient means
for enrichment of the mRNA, the use of microsomal mRNA
rather than total mRNA as the starting material was probably
just as important. Second, cell-free translations were always
carried out in the presence of dog pancreas microsomes (15).
In our experience the microsomes promote the translation, pro-
tect the protein against proteolytic degradation, and, by re-
moving the signal sequence and by adding the core sugars, allow
the expression of most if not all antigenic determinants present
on the cell surface form of the protein...Third, the availability
of a specific antiserum strongly reactive against the. microsomal
form of the P chain was important. It seems that the use of
NaDodSOjpolyacrylamide gel electrophoresis,. which dena-
tures the protein, to some extent, to isolate 3 chains for im-
munization.provided us with an antiserum that reacted better
with the isolated (3 chains than with the intact HLA-DR
antigens.
The cDNA clone pDR-,8-1 contains an insert of 1070 base
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FIG. 5. Predicted amino acid sequences of pDR-,3-1, Raji HLA-DR antigen ,achain sequence determined on unlabeled material, and radiochem-
ical amino acid sequence of the HLA-DR antigen chains biosynthetically labeled with leucine, phenylalanine, tyrosine, and methionine. Amino
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pairs. Because pDR-(3-1 comprises the nucleotide sequence
corresponding to the NH2 terminus of a P chain and because
P chains should be composed of about 230 amino acids, as cal-
culated from the apparent molecular weight of nonglycosylated
(3-chains, pDR-j3-1 should provide the entire nucleotide se-
quence of the translated portion of a P chain. In addition, ap-
proximately 300 base pairs of untranslated sequence should be
obtained. This is obviously less than the complete untranslated
region because our preliminary nucleotide sequence analysis
at the right-hand side of the pDR-(3-1 insert fails to reveal a
poly(A) site. Apart from providing the protein sequence for a
,( chain, the pDR-,8-1 clone should prove useful in analyses of
the structure and organization ofthe HLA-D locus and its genes.
Data on HLA-DR antigen /3-chain amino acid sequences are
scarce. In fact, 15 positions in the NH2-terminal region appear
to have been identified (10, 33, 34). This situation together with
the fact that ,( chains display an extensive genetic polymorphism
prompted us to elucidate the NH2-terminal sequence of HLA-
DR antigen (3 chains derived from Raji cells. The amino acid
sequence found for unlabeled (3 chains demonstrated the het-
erogeneity of the material because multiple residues were ob-
tained in some positions. We expected to find two amino acid
residues in some positions because the Raji cells express two
alleles, DO3 and Du6, at the HLA-D locus. However, three
amino acid residues were obtained for four positions. This sug-
gests that the HLA-DR antigens may comprise more than two
types of(3 chains. In fact, recent data strongly indicate that the
HLA-D region may contain two loci (11, 12). The present ob-
servations are compatible with such an idea because in three
of the four positions where the amino acid sequence determi-
nation revealed three amino acid residues, pDR-,(31 contained
yet a fourth amino acid residue. Consequently, Raji cells may
be heterozygous also at a second HLA-D locus.
It is well established that the murine counterpart ofthe HLA-
D locus, the I region, contains two subloci. A similar situation
has been noted in the rat (35) and in the chicken (36). Unfor-
tunately, not enough amino acid sequence information is avail-
able relative to murine I-A and I-E/C (3 chains to allow any
conclusion as to whether pDR-3-1 may be the equivalent of an
I-A or an I-E/C (3 chain.
The NH2-terminal amino acid sequence determinations were
carried out by two entirely different techniques. This had to be
done because the isolation procedures used may have provided
highly purified HLA-DR antigens that were not quantitatively
representative of the Raji cell HLA-DR antigens. Indeed, the
two protein sequences only displayed 64% homology at the
positions available for comparison. It is interesting to note that
the four positions in the radiochemical sequence that differed
from the corresponding amino acid sequence of the unlabeled
(3 chains were identical to the pDR-,(31. Therefore, the two
protein sequences firmly establish that the isolated cDNA clone
corresponds to the mRNA of an HLA-DR antigen 3 chain.
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